等待開盤 12-18 09:30:00 美东时间
+0.210
+0.31%
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从35美元升至36美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.75美元升至8美元
12-09 10:32
Key Takeaways Hardship-loan demand is increasing as more households encounter ...
12-02 03:00
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从4美元升至9美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从32美元升至38美元
11-25 10:27
Citizens analyst David Scharf maintains OneMain Holdings (NYSE:OMF) with a Market Outperform and lowers the price target from $70 to $68.
11-24 19:32
Navigating the current market environment has become increasingly challenging for investors, as uncertainty persists and clear forward guidance remains limited with the U.S. government shutdown. The m...
11-12 22:38
今日重点评级关注:花旗:维持Caribou Biosciences"买入"评级,目标价从5美元升至8美元;HC Wainwright & Co.:上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入",目标价30美元
11-04 10:31
OneMain Holdings (OMF) declares $1.05/share quarterly dividend. Forward yield 7.1% Payable Nov. 14; for shareholders of record Nov. 10; ex-div Nov. 10. See OMF Dividend Scorecard, Yield Chart, & Divid...
11-03 14:47
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据OneMain 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收达到16亿美元,同比增长9% - 利息收入14亿美元,同比增长9% - 其他收入2亿美元,同比增长11%(主要由贷款出售收益和信用卡业务增长驱动) **盈利能力:** - GAAP净利润1.99亿美元,每股1.67美元,同比增长27%(去年同期每股1.31美元) - DNI调整后净利润每股1.90美元,同比大幅增长51%(去年同期1.26美元) - 资本生成2.72亿美元,同比增长29%;每股资本生成2.28美元,同比增长3
11-03 12:19
OneMain Holdings shares are trading higher after the company reported better-th...
11-01 00:51
Companies Reporting Before The Bell • T. Rowe Price Group (NASDAQ:TROW) is esti...
10-31 19:11